Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

DOXORUBICIN-TEVA

Package(a):
VIAL (solution for injection): 1 x 25 ml.
Dosage(a):
Recommended total dose: 550 mg/m² I.V. Please refer to the manufacturer for further details. Recommended schedule: 60-75 mg/m² as single I.V. at 21-day intervals. Please refer to the manufacturer for further information.
Prescribing Restrictions:  None

Package(b):
LYOPHILIZED POWDER: FOR INJECTION: Vials: 1 x 10 mg, 50 mg.
This package has been discontinued.
Dosage(b):
Recommended total dose: 550 mg/m² I.V. Please refer to the manufacturer for further details. Recommended schedule: 60-75 mg/m² as single I.V. at 21-day intervals. Please refer to the manufacturer for further information.
Prescribing Restrictions:  None

Package(c):
VIAL (solution for injection): 1 x 100 ml.
Dosage(c):
Recommended total dose: 550 mg/m² I.V. Please refer to the manufacturer for further details. Recommended schedule: 60-75 mg/m² as single I.V. at 21-day intervals. Please refer to the manufacturer for further information.
Prescribing Restrictions:  None


Indications:
To produce regression in disseminated neoplastic conditions, e.g. acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue/bone sarcoma, carcinoma of the breast, ovary, transient cell bladder carcinoma, thyroid carcinoma, lymphoma of both Hodgkin's and non Hodgkin's bronchogenic carcinoma, gastric carcinoma.
Contra-Indications:
Please refer to the manufacturer for further information.
Special Precautions:
Please refer to the manufacturer for further information.
Side Effects:
Please refer to the manufacturer for further information.
Drug Interactions:
Please refer to the manufacturer for further information.